This can occur through a variety of mechanisms, which may involve a loss-of-function mutation or epigenetic silencing of BMPR2 [72,73,74], or through paracrine induction of BMP antagonists such as Gremlin on tumour-associated stromal cells [75]. This evidence concerns the gene GREM1 and neoplasm.